Development of new drug-regimens against multidrug-resistant tuberculosis

World Health Organization, 2015 Central TB division, 2016 World Health Organization, 2014 http://www.tbfacts.org/drug-resistant-tb-in-india/#sthash.IrCYIdER.dpuf. Accessed 21 November 2016. Mathys, 2009, Molecular genetics of para aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 53, 2100, 10.1128/AAC.01197-08 World Health Organization. http://www.who.int/features/qa/79/en/. Accessed 22 December 2016. Sharma, 2004, Extrapulmonary tuberculosis, Indian J Med Res, 120, 354 Zumla, 2013, Tuberculosis, N Engl J Med, 368, 745, 10.1056/NEJMra1200894 CDC, 2006, Notice to readers: revised definition of extensively drug-resistant tuberculosis, MMWR, 55, 1176 Ramaswamy, 1998, Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update, Tuber Lung Dis, 79, 3, 10.1054/tuld.1998.0002 Lew, 2011, TubercuList–10 years after, Tuberculosis, 91, 1, 10.1016/j.tube.2010.09.008 Bastian, 2000, Directly observed treatment, short-course strategy and multidrugresistant tuberculosis: are any modifications required?, Bull World Health Organ, 78, 238 Vareldzis, 1994, Drug-resistant tuberculosis :laboratory issues. World Health Organization recommendations, Tuber Lung Dis, 75, 1, 10.1016/0962-8479(94)90096-5 Citron, 1987, Tuberculosis, 5.278 Dye, 2002, Worldwide incidence of multidrug-resistant tuberculosis, J Infect Dis, 185, 1197, 10.1086/339818 Diacon, 2012, Phase II dose-ranging trial of the early bactericidal activity of PA-824, Antimicrob Agents Chemother, 56, 3027, 10.1128/AAC.06125-11 Mukherjee, 2011, Nitroimidazoles for the treatment of TB: past, present and future, Future Med Chem, 3, 1427, 10.4155/fmc.11.90 Stover, 2000, A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis, Nature, 405, 962, 10.1038/35016103 Diacon, 2012, 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial, Lancet, 380, 986, 10.1016/S0140-6736(12)61080-0 Ryan, 2014, Delamanid: first global approval, Drugs, 74, 1041, 10.1007/s40265-014-0241-5 Andries, 2005, A diarylquinoline drug active on the ATP synthase of Mycobacterium tubercu-losis, Science, 307, 223, 10.1126/science.1106753 Koul, 2007, Diarylquinolines target subunit c of mycobacterial ATP synthase, Nat Chem Biol, 3, 323, 10.1038/nchembio884 European Medicines Agency. CHMP Assessment Report: SIRTURO. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_Initial_authorisation/human/002614/WC500158728.pdf. Accessed 25 December 2016. Andries, 2005, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Science, 307, 223, 10.1126/science.1106753 Pym, 2015, Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis, Eur Respir J, 724 International Union against Tuberculosis and Lung Disease. Current Trials: STREAM clinical trial to test first all-oral MDR-TB treatment regimen. www.theunion.org/what-we-do/research/clinical-trials. Accessed 27 December 2016. Nunn, 2014, Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial, Trials, 15, 353, 10.1186/1745-6215-15-353 http://www.outsourcing-pharma.com/Preclinical-Research/Macrolide-drug-class-extended-to-treat-TB. Accessed 9 January 2017. http://www.newtbdrugs.org/pipeline/discovery. Accessed 9 January 2017. Zhu, 2008, Structure-activity relationships of macrolides against Mycobacterium tuberculosis, Tuberculosis, 88, S49, 10.1016/S1472-9792(08)70036-2 Griffith, 2007, An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, Am J Respir Crit Care Med, 175, 367, 10.1164/rccm.200604-571ST Mogayzel, 2013, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med, 187, 680, 10.1164/rccm.201207-1160OE Glassford, 2016, Ribosome-templated azide–alkyne cycloadditions: synthesis of potent macrolide antibiotics by in situ click Chemistry, J Am Chem Soc, 138, 3136, 10.1021/jacs.5b13008 World Health Organization, 2011 Vinh, 2009, Linezolid: a review of safety and tolerability, J Infect, 59, S59, 10.1016/S0163-4453(09)60009-8 Ippolito, 2008, Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ri-bosomal subunit, J Med Chem, 51, 3353, 10.1021/jm800379d Leach, 2011, Linezolid, the first oxazolidinone an-tibacterial agent, Ann N Y Acad Sci, 1222, 49, 10.1111/j.1749-6632.2011.05962.x Ashtekar, 1991, Oxazolidinones, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis, Diagn Microbiol Infect Dis, 14, 465, 10.1016/0732-8893(91)90002-W Migliori, 2009, A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis, Eur Respir J, 34, 387, 10.1183/09031936.00009509 Shaw, 2011, The oxazolidinones: past, present, and future, Ann N Y Acad Sci, 1241, 48, 10.1111/j.1749-6632.2011.06330.x Balasubramanian, 2014, Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis, Antimicrob Agents Chemother, 58, 495, 10.1128/AAC.01903-13 Prokocimer, 2011, Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections, Antimicrob Agents Chemother, 5, 583, 10.1128/AAC.00076-10 Schaadt, 2009, In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent, Antimicrob Agents Chemother, 53, 3236, 10.1128/AAC.00228-09 Makobongo, 2013, In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori, PLoS One, 8, 68917, 10.1371/journal.pone.0068917 Horwith, 2007, Phase 1 safety and pharmacokinetics of SQ109, a new diamine antituberculosis drug Protopopova, 2005, Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines, J Antimicrob Chemother, 56, 968, 10.1093/jac/dki319 Nikonenko, 2004, Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis, Antimicrob Agents Chemother, 48, 4550, 10.1128/AAC.48.12.4550-4555.2004 US Department of Health and Human Services, 2010 Libermann, 1956, Preparation of new pyridinic thioamides active in experimental tuberculosis, CR Hebd Seances Acad Sci, 242, 2409 Nunn, 2005, Tuberculosis control in the era of HIV, Nat Rev Immunol, 5, 819, 10.1038/nri1704 Sala, 2011, Tuberculosis drugs: new candidates and how to find more, Future Microbiol, 6, 617, 10.2217/fmb.11.46 Ma, 2010, Global tuberculosis drug development pipeline: the need and the reality, Lancet, 375, 2100, 10.1016/S0140-6736(10)60359-9 Tandon, 2016, Tackling drug-resistant tuberculosis: current trends and approaches, Mini Rev Med Chem